Excerpt about the acquisition of Biohaven taken from Pfizer’s 10-K for the fiscal year that ended on December 31, 2022. Acquisition of Biohaven On October 3, 2022, we acquired Biohaven, the maker of rimegepant, an innovative therapy approved for acute treatment of migraines. Under the terms of the agreement, we acquired all outstanding common shares of Biohaven not already owned by us for $148.50 per share. On the date of the acquisition, we transferred cash of $11,500 million to the shareholders of Biohaven. This acquisition follows on the November 2021 collaboration agreement in which we acquired 2.6 percent of Biohaven’s common stock. On October 3, 2022, this 2.6 percent equity interest had a fair (carrying) value of $200 ($150) million. Per the acquisition agreement, certain former shareholders of Biohaven transferred their shares in exchange for the right to receive tiered royalties from Pfizer on any annual net sales of rimegepant in the U.S. in excess of $5.25 billion. This contingent consideration was determined to have a fair value as of October 3, 2022, of $100 million. In connection with this business combination, on October 3, 2022, we recorded the following identifiable assets and liabilities: What effect did the acquisition of Biohaven have on Pfizer's Equity and Income (in millions of U.S. dollars) Trade accounts receivable 398 Inventories 817 Identifiable intangible assets 12,100 Total 13,315 Other current liabilities 477 Long-term debt 1,400 Deferred tax liabilities 566 Total 2,443